Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (Currently Amended) A method of administering a therapeutic agent to a subject suffering from a multi-drug resistant neoplastic condition ~~cell expressing P-glycoprotein~~, comprising

C3

preparing a conjugate composed of (i) a carrier; (ii) a folate ligand attached to the carrier; and (iii) a therapeutic agent associated with the carrier; and

administering the conjugate to ~~a~~ said subject;

whereby said administering is effective to achieve accumulation of said therapeutic agent in ~~said~~ cells associated with said neoplatic condition.

2. (original) The method of claim 1, wherein said preparing includes preparing a conjugate where the carrier is a natural or synthetic polymer.

3. (original) The method of claim 1, wherein said preparing includes preparing a conjugate where the carrier is a protein or peptide macromolecule.

4. (original) The method of claim 1, wherein said preparing includes preparing a conjugate where the carrier is a liposome having a surface coating of hydrophilic polymer chains and the folate ligand is attached to a distal end of the polymer chains.

5. (original) The method of claim 4, wherein the polymer is polyethyleneglycol having a molecular weight of at least about 3,500 Daltons.

6. (original) The method of claim 1, wherein said preparing includes preparing a conjugate where the therapeutic agent is a chemotherapeutic drug.

7. (original) The method of claim 1, wherein said preparing includes preparing a conjugate where the therapeutic agent is an anthracycline antiobiotic.

8. (currently amended) The method of claim 7, wherein the anthracycline ~~antiobiotic~~ antibiotic is selected from the group consisting of doxorubicin, daunorubicin, epirubicin idarubicin, mitoxantrone and an anthraquinone drug.

9. (Currently Amended) A method of administering to a subject suffering from a multi-drug resistant neoplastic condition that includes one or more cells in which a therapeutic compound ~~which~~ in free form does not accumulate ~~in the cell~~, comprising,

preparing liposomes composed of (i) vesicle-forming lipids and including a vesicle forming lipid derivatized with a hydrophilic polymer chain having a free distal end, (ii) a folate ligand attached to the free distal end of at least a portion of the hydrophilic polymer chains, and (iii) a therapeutic agent entrapped in the liposomes; and

administering the liposomes to ~~a~~ said subject;

whereby accumulation of the compound in the cell is achieved in an amount sufficient for cytotoxicity of said cell.

10. (original) The method of claim 9, wherein said preparing includes preparing liposomes where the hydrophilic polymer is polyethylene glycol having a molecular weight of at least about 3,500 Daltons.

11. (original) The method of claim 9, wherein said preparing includes preparing liposomes where the therapeutic agent is an anthracycline antiobiotic.

12. (currently amended) The method of claim 11, wherein the anthracycline ~~antiobiotic~~ antibiotic is selected from the group consisting of doxorubicin, daunorubicin, epirubicin idarubicin, mitoxantrone and an anthraquinone drug.

Claims 13-21 (Canceled)

22. (new) The method of claim 9, wherein said portion of hydrophilic polymer chains bearing a folate ligand having a greater molecular weight than said hydrophilic chains with no folate ligand.

23. (new) The method of claim 22, wherein said portion of hydrophilic polymer chains bearing a folate ligand is comprised of polyethylene glycol having a molecular weight of at least 3350 Daltons.